Skip to main content

TorreyPines, Eisai Extend Genetic Research Collaboration for Alzheimer's

NEW YORK (GenomeWeb) - TorreyPines Therapeutics and Eisai have extended an agreement to identify and validate genes that may be used as targets for Alzheimer's drug compounds, TorreyPines said yesterday.
 
The research collaboration, which the companies began in 2005, is using whole-genome family-based association screening to identify genes associated with Alzheimer's disease.
 
TorreyPines, based in La Jolla, Calif., will receive an upfront payment and funding for the research for another year, and Eisai will have exclusive rights for first negotiation and refusal for gene targets that come from the research.
 
TorreyPines said the companies also are involved in a separate agreement to find novel compounds that may be used to treat Alzheimer's disease.
 
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.